GSK, Spero reveal full Phase 3 data for oral antibiotic, set for end-of-year filing

GSK and Spero Therapeutics are taking their oral antibiotic to the FDA after reporting the full Phase 3 non-inferiority data. The companies said Monday that tebipenem HBr performed no worse than ...